How Platelet-Rich Plasma Stimulates Hair Growth
What is platelet-rich plasma and how does it stimulate hair growth?
Everything in the syringe came out of your own arm about fifteen minutes earlier, which is the first thing worth knowing before you weigh this up. A small draw gets spun down until the platelets are concentrated into a few millilitres of plasma, and those platelets carry the growth signals your body already uses to repair tissue. The catch that decides whether any of it matters for you is simple: this wakes up follicles that are still there, and it can't build ones that aren't.
Platelet-rich plasma concentrates a patient's own platelets to roughly two to six times their normal blood level and delivers that growth-factor signal into the scalp dermis, where it can stimulate follicles that still exist but cannot regenerate follicles already replaced by fibrous tissue.
What exactly is in platelet-rich plasma and how is it separated from a sample of whole blood?
Your blood is already sorted by weight, and a centrifuge just makes that sorting happen in minutes instead of hours. Whole blood runs about 55 percent plasma, with red cells taking up most of the rest and a thin layer between the two called the buffy coat holding the platelets and white cells. Everything the treatment depends on lives in that thin layer, so how it's harvested is the whole game.
- The draw: Blood goes into tubes holding an anticoagulant such as sodium citrate, which binds calcium so the platelets don't clot before they're used.
- The spin: Several thousand rotations per minute for five to fifteen minutes sinks the red cells and lifts the platelet-poor plasma, leaving the platelet-rich layer sitting just above the red cell line.
- The harvest: A single spin draws plasma off just above that boundary for a moderate concentration and a higher total platelet yield; a double spin pellets the platelets and resuspends them in a few millilitres for a much higher concentration in less volume.
- The clock: Platelets start degranulating and losing potency once separated, so the plasma is injected in the same appointment rather than stored.
A draw of twenty to sixty millilitres yields roughly three to eight millilitres of injectable plasma at around two to six times the patient's own baseline platelet count, which for most people lands near one million platelets per microlitre.
Which growth factors do concentrated platelets release once they are activated?
Most people picture platelets as clotting cells and stop there, which misses what's actually being delivered. Each platelet carries dozens of alpha granules holding well over three hundred distinct proteins, and six of them carry most of the reasoning behind using this on a scalp. Think of it less as a drug and more as a repair order your own body already knows how to read.
- Platelet-derived growth factor: Drives cell proliferation and pulls repair cells to the injection site.
- Vascular endothelial growth factor: Prompts new capillary branches around the follicle.
- Insulin-like growth factor 1: Strongly linked to holding the follicle in its growing phase longer.
- Transforming growth factor beta: Balances new tissue against scar tissue, so its dose and context matter more than sheer quantity.
Around 70 percent of the stored growth factors are released within the first ten minutes of activation and effectively all of them within the first hour, after which platelets keep synthesising smaller amounts for up to about a week.
How do those growth factors act on the dermal papilla and the stem cells that sit in the follicle?
Here's the part that explains why hairs can come back thicker and not just more numerous. The dermal papilla is a small cluster of cells cupped at the base of each follicle, and it works as the instruction set: it decides how long growth runs, how thick the shaft gets, and when the follicle packs up. Grow that papilla and you change the fibre, not just the count.
- The papilla: Platelet-derived and fibroblast growth factors push its cells to multiply, and a larger, more populous papilla tracks directly with a thicker shaft.
- The bulge: A reservoir of epithelial stem cells sitting where the arrector pili muscle attaches, supplying the new cells needed every time a follicle restarts a cycle.
- The survival switches: Wnt and beta-catenin signalling governs entry into a new growth cycle, while Akt activation raises the anti-apoptotic protein Bcl-2 and slows the cell attrition that shrinks a papilla a little more each cycle.
Cultured dermal papilla cells exposed to platelet-rich plasma show measurably increased proliferation and raised expression of growth-promoting signals, which is the cleanest evidence that the effect on the cell is direct rather than only a downstream result of better blood supply.
How does the injection shift follicles between the resting phase and the growing phase of the hair cycle?
Every follicle on your head runs its own repeating cycle, and thinning is really a ratio problem inside that cycle. On a healthy scalp roughly 80 to 90 percent of hairs are actively growing and only 10 to 15 percent are resting; in progressive thinning that balance tips the wrong way and each new shaft comes in finer than the last. The treatment aims squarely at the ratio rather than at any single hair.
- Anagen: Active growth, running two to six years on the scalp, which is why scalp hair reaches the length it does.
- Catagen: A short regression stage of about two to three weeks while the lower follicle involutes.
- Telogen: Rest, lasting anywhere from some weeks to the better part of a year, ending when the old shaft sheds and a new anagen begins.
Scalp hair grows at roughly one centimetre a month, so shortening the telogen idle and extending anagen buys both length and calibre, but because follicles cycle asynchronously no single session catches them all, which is why an initial series is spaced roughly four to six weeks apart.
What part does new blood vessel formation around the follicle play in the response?
A follicle in full growth is one of the hungriest structures in your skin, turning out new keratinocytes at a rate comparable with the gut lining. It can't do that on a thin supply line. Each growing follicle sits inside its own basket of capillaries, and studies of pattern thinning have found that basket is sparser around miniaturised follicles.
- What VEGF does: Prompts existing endothelial cells to multiply and sprout new capillary branches, and animal work links that to both follicle size and shaft calibre.
- Where it ranks: Supporting mechanism, not the headline one. Better perfusion doesn't instruct a follicle to grow; it removes a ceiling on how well the follicle can carry out an instruction it already has.
- Why it fades: Capillary networks regress once the signals maintaining them fade, so the new supply isn't permanent either.
Reduced perifollicular capillary density is documented around miniaturised follicles in pattern thinning, and while the direction of causation is still argued, a follicle restarting a full growth cycle needs a supply network able to feed it either way.
Why does the preparation method change what is actually being injected into the scalp?
Two syringes described by the same three words can hold genuinely different products, and that's the single biggest complication in reading this field. Three things move: whether the white cells are kept, how concentrated the platelets are, and how the separation is done. If you're comparing two providers or two studies, you're often not comparing the same material at all.
| Criteria | Closed commercial system | Open manual preparation |
|---|---|---|
| Separation | Proprietary separator tube or gel barrier, validated spin protocol | Plasma pipetted between ordinary tubes |
| Reproducibility | Consistent output run to run | More operator-to-operator variation |
| Contamination risk | Sealed pathway, largely removed | Sample exposed to the room |
| Adjustability and cost | Fixed protocol, higher cost per treatment | Cheaper and more adjustable |
Classification schemes describe a preparation by its platelet count, leukocyte content and activation method rather than by the name on the kit, because concentration isn't linearly better and laboratory evidence shows pushing it too high can reduce rather than raise the angiogenic response, which is why roughly two to six times baseline is the target.
Which patterns of hair loss are biologically capable of responding to this mechanism?
Everything turns on one question: is there still a follicle there. This stimulates what exists and cannot create what doesn't, so before anyone talks about sessions, the scalp needs looking at under magnification for miniaturised hairs and open follicular pores. Where you sit on this list matters more than any protocol detail.
The clearest poor candidates are long-established bare scalp, an active scarring condition, or an unaddressed systemic contributor such as iron deficiency, thyroid dysfunction, low vitamin D or a medication side effect, and each of those should be ruled out before injections are considered.
What measurable changes in hair density and shaft thickness has published research recorded?
Measurement here is more standardised than the treatment protocols are, which is a strange position for a field to be in. A marked target area of about one square centimetre is photographed under magnification at baseline and again at follow-up, so hairs are counted and shaft diameters measured in micrometres by the same software each time. What the numbers show is a real direction of effect sitting on top of genuinely weak evidence.
Pooled analyses report a positive direction of effect alongside low strength of evidence, high heterogeneity between studies and evident publication bias, and in the United States the approved treatments for pattern hair loss remain topical minoxidil and finasteride, which this is not.
How does the mechanism differ from the way topical and oral hair loss drugs work?
The cleanest way to separate these is by where each one steps into the problem. One works on blood flow at the follicle, one works upstream on the hormone driving the loss, and one delivers repair signalling straight into the tissue. That's also why they're usually presented as complementary rather than as a choice between three.
| Criteria | Topical minoxidil | Oral finasteride | Injected plasma |
|---|---|---|---|
| Point of action | Blood flow and potassium channels at the follicle | Blocks conversion of testosterone to DHT | Growth-factor burst into the dermis |
| Addresses the cause | No | Yes, the only one of the three | No, works downstream of it |
| Commitment | Applied once or twice daily, indefinitely | Daily tablet, indefinitely | Initial series, then maintenance a few times a year |
| Risk shape | Local, application-related | Systemic while taken, with effects reported to persist in some patients after stopping | Local and time-limited: soreness, swelling, bruising, small infection risk |
Because the hormonal driver in pattern loss continues unchanged, an injection-only approach is holding ground against a process that's still running, which is why combination protocols pairing it with a hormonal blocker or a topical are common in practice.
Why does the effect fade over time instead of lasting permanently?
Nothing in this mechanism removes the reason your hair was thinning in the first place. The genetic sensitivity of the follicle sits exactly where it did before the first injection, so what you're really doing is resupplying follicles that stay under continuing pressure. Treat it as an ongoing programme with a recurring cost and the decision is an honest one; treat it as a cure and it will disappoint.
- The signal is a pulse, not a change: Platelets release the bulk of their growth factors within an hour and are spent within about a week, so the tissue's chemistry doesn't stay altered.
- The pressure never lifts: Once the stimulus is gone the follicle drifts back toward whatever the underlying condition dictates, and studies with longer follow-up have shown density declining again.
- Stopping isn't a penalty: Treated follicles aren't damaged and don't shed faster than they otherwise would; they simply resume the trajectory they were on, so gains taper over the following cycles rather than dropping away suddenly.
Most published studies haven't followed patients beyond six months, which is why maintenance is normally scheduled at roughly two to four sessions a year rather than left until the loss becomes visible again.
